Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4Sarcoma 2Plasma cell 2Myeloid 2Gastrointestinal 2Dermatologic 2Classical hematology 2Thoracic 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 141Lenalidomide 60Bortezomib 56Calcium Dobesilate 47Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10Cyclosporine 9pembrolizumab 8isatuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Gene Expression Profiling × Plasma cell × Clear all
NCT01155583 2020-11-16

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1/2 Completed
45 enrolled 20 charts
Plasma cell

Multiple Myeloma

NCT01212952 2020-04-17

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
50 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡